• Users Online: 283
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
This article has been cited by
1Improving the fate of severely infected patients: the promise of anti-toxin treatments and superiority trials
Samareh Azeredo da Silveira,Antonio Perez
Expert Review of Anti-infective Therapy.2017;15(11)973
[DOI]
2CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial
Pierre-François Laterre,Gwenhael Colin,Pierre-François Dequin,Thierry Dugernier,Thierry Boulain,Samareh Azeredo da Silveira,Frédéric Lajaunias,Antonio Perez,Bruno François
The Lancet Infectious Diseases.2019;19(6)620
[DOI]
3Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain
Antoni Torres,Matteo Bassetti,Tobias Welte,Simone Rivolo,Edit Remak,Carmen Peral,Claudie Charbonneau,Jennifer Hammond,Wajeeha Ansari,Santiago Grau
Journal of Medical Economics.2020;23(2)148
[DOI]
4Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug
Samareh Azeredo da Silveira,Andrew F. Shorr
Antibiotics.2020;9(2)94
[DOI]
5CAL02 Liposomes and Other Antitoxins: A New Generation of Anti-Infectives
Samareh Azeredo da Silveira,Antonio Perez
Clinical Pulmonary Medicine.2018;25(3)84
[DOI]
Feedback

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal